Mary C. Beckerle - Feb 14, 2025 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
Director
Signature
/s/ Nina Ayer, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Feb 14, 2025
Transactions value $
-$231,731
Form type
4
Date filed
2/19/2025, 08:32 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $194K +8.35K +24.38% $23.24 42.6K Feb 14, 2025 Direct F1
transaction EXEL Common Stock Sale -$291K -8.35K -19.6% $34.87 34.3K Feb 14, 2025 Direct F1, F2
transaction EXEL Common Stock Sale -$135K -3.86K -11.25% $34.90 30.4K Feb 14, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -8.35K -27.08% $0.00 22.5K Feb 14, 2025 Common Stock 8.35K $23.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 30,406 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
F2 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.87 to $34.88. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3 The option, representing the right to purchase a total of 30,848 shares of Common Stock, became fully exercisable on January 5, 2024.